Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Narrative)

v3.7.0.1
Subsequent Events (Narrative)
 1 Months Ended 6 Months Ended
Jul. 19, 2017
USD ($)
$ / shares
shares
Jul. 13, 2017
USD ($)
$ / shares
shares
Jul. 07, 2017
USD ($)
$ / shares
shares
Jul. 17, 2017
USD ($)
Number
Jun. 30, 2017
USD ($)
shares
Proceeds from warrants exercised         $ 425,097
Stock Issued During Period, Shares | shares         163,499
Subsequent Event [Member]          
Warrants exercised | shares 45,000   5,000    
Proceeds from warrants exercised $ 108,000   $ 11,000    
Stock Issued During Period, Shares | shares 45,000   5,000    
Option granted to purchase shares | shares   10,000      
Options vesting date   July 13, 2018      
Option expiry term   5 years      
Exercise price | $ / shares $ 2.40 $ 5.00 $ 2.20    
Stock price | $ / shares   $ 3.15      
Volatility   78.41%      
Risk free rate   2.16%      
Expected trem   6 years      
Fair market value   $ 19,068      
Subsequent Event [Member] | Clinical Study Agreement [Member]          
Enrollment period       3 years  
Maximum payment due       $ 3,000,000  
Number of samples | Number       13,500  
Quarterly installments       $ 250,000